A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder / Maria A. Sullivan en The American Journal of Psychiatry, Año 2019 - Vol. 176 - No.2 (Febrero)

Público ISBD [artículo]  inThe American Journal of Psychiatry > Año 2019 - Vol. 176 - No.2 (Febrero) . - pp. 129-137 Título : A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder Tipo de documento: texto impreso Autores: Maria A. Sullivan, Autor ; Adam Bisaga, Autor ; Martina Pavlicova, Autor Fecha de publicación: 2019 Artículo en la página: pp. 129-137 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Inyección de naltrexona, Antagonista opioide, Trastorno de uso de opioides, Naltrexona oral, Retención de tratamiento Resumen: The oral formulation of the opioid antagonist naltrexone has shown limited effectiveness for treatment of opioid use disorder due to poor adherence. Long-acting injection naltrexone (XR-naltrexone), administered monthly, circumvents the need for daily pill taking, potentially improving adherence, and has been shown to be superior to placebo in reducing opioid use over 6 months of treatment. Link: ./index.php?lvl=notice_display&id=20489 [artículo] A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder [texto impreso] / Maria A. Sullivan, Autor ; Adam Bisaga, Autor ; Martina Pavlicova, Autor . - 2019 . - pp. 129-137. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The American Journal of Psychiatry > Año 2019 - Vol. 176 - No.2 (Febrero) . - pp. 129-137 Palabras clave: Inyección de naltrexona, Antagonista opioide, Trastorno de uso de opioides, Naltrexona oral, Retención de tratamiento Resumen: The oral formulation of the opioid antagonist naltrexone has shown limited effectiveness for treatment of opioid use disorder due to poor adherence. Long-acting injection naltrexone (XR-naltrexone), administered monthly, circumvents the need for daily pill taking, potentially improving adherence, and has been shown to be superior to placebo in reducing opioid use over 6 months of treatment. Link: ./index.php?lvl=notice_display&id=20489

Sublingual buprenorphine-naloxone compared with injection naltrexone for opioid use disorder / Edward V. Nunes en The American Journal of Psychiatry, Año 2021 - Vol. 178 - No.7 (Julio)

Público ISBD [artículo]  inThe American Journal of Psychiatry > Año 2021 - Vol. 178 - No.7 (Julio) . - pp. 660-671 Título : Sublingual buprenorphine-naloxone compared with injection naltrexone for opioid use disorder : potential utility of patient characteristics in guiding choice of treatment Tipo de documento: texto impreso Autores: Edward V. Nunes, Autor ; Jennifer M. Scodes, Autor ; Martina Pavlicova, Autor Fecha de publicación: 2021 Artículo en la página: pp. 660-671 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Buprenorfina, Inyección de liberación prolongada de naltrexona, Trastorno por consumo de opioides, Personas sin hogar, Justicia penal, Recaída, Inducción de naltrexona Resumen: Sublingual buprenorphine-naloxone and extended-release injection naltrexone are effective treatments, with distinct mechanisms, for opioid use disorder. The authors examined whether patients’ demographic and clinical characteristics were associated with better response to one medication or the other. Link: ./index.php?lvl=notice_display&id=26643 [artículo] Sublingual buprenorphine-naloxone compared with injection naltrexone for opioid use disorder : potential utility of patient characteristics in guiding choice of treatment [texto impreso] / Edward V. Nunes, Autor ; Jennifer M. Scodes, Autor ; Martina Pavlicova, Autor . - 2021 . - pp. 660-671. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The American Journal of Psychiatry > Año 2021 - Vol. 178 - No.7 (Julio) . - pp. 660-671 Palabras clave: Buprenorfina, Inyección de liberación prolongada de naltrexona, Trastorno por consumo de opioides, Personas sin hogar, Justicia penal, Recaída, Inducción de naltrexona Resumen: Sublingual buprenorphine-naloxone and extended-release injection naltrexone are effective treatments, with distinct mechanisms, for opioid use disorder. The authors examined whether patients’ demographic and clinical characteristics were associated with better response to one medication or the other. Link: ./index.php?lvl=notice_display&id=26643

---

1 (1 - 2 / 2)